Navigation Links
Diabetes Alliance to Feature 17 Presentations for Linagliptin and Investigational Compound Empagliflozin^ During the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Date:9/17/2013

RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 17, 2013 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (Lilly; NYSE: LLY) today announced they will feature five oral and 12 poster presentations for linagliptin and the investigational compound empagliflozin^ at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD), which will take place in Barcelona from September 23 – 27.

Empagliflozin Data
A total of eight clinical abstracts for the investigational agent empagliflozin will be presented. Empagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor being investigated for the reduction of blood glucose levels in adults with type 2 diabetes (T2D). The emerging SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose re-absorption by the kidney.

^Empagliflozin is an investigational compound. Its safety and efficacy have not been established.

Details of clinical presentations for empagliflozin are as follows:1

Tuesday, September 24, 12:30–1:30 CET, General Poster Session 

  • Empagliflozin as Add-on to Basal Insulin for 78 Weeks Improves Glycemic Control and Weight Loss in Insulin-Treated Type 2 Diabetes (T2DM) (Presenting Author: J. Rosenstock) [Poster No. 931]
  • Safety and Efficacy of Empagliflozin Monotherapy in a 52-Week Study in Japanese Patients with Type 2 Diabetes Mellitus (Presenting Author: H. J. Woerle) [Poster No. 930]
  • Metabolic Response to Sodium Glucose Transporter 2 (SGLT2) Inhibition with Empagliflozin in Patients with Type 2 Diabetes (T2D) (Presenting Author: E. Ferrannini) [Poster No. 932]

Tuesday
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
2. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
3. Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic
4. CASiGEN Pharma Receives A World-wide Exclusive License From GIBH To Bring New Potential Diabetes Treatments To The Global Market
5. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
6. Valeritas Inc. Selects dLifes New Diabetes Patient Engagement Solution For Valeritas V-go Disposable Insulin Delivery Device
7. Jentadueto® (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with type 2 diabetes in Europe
8. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
9. JDRF and BD Collaborate to Develop More Accurate and Reliable Glucose Monitoring Devices for People with Type 1 Diabetes
10. Eleven Integrated Health Systems Form Largest Private-Sector Diabetes Registry in United States
11. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , September 1, 2015 ... on the basis of sectors, products & services ... globally coupled with the increasing demand of advanced ... expected to propel the growth for bioinformatics market. ... information efficiently is known as bioinformatics. Decreasing cost ...
(Date:9/1/2015)... , Aug. 31, 2015 Research and ... the "Regulatory Affairs for Support Staff (London, UK ... This two day course provides an ... drug development and has been designed specifically for those ... You will gain an overview of EU regulatory procedures ...
(Date:9/1/2015)... LONDON , September 1, 2015 - ... of GARFIELD-AF R egistry data presented ... real-world insights on the evolution of ... -   The first-ever two-year ... showcased at ESC Congress 2015 expose that all-cause death was the most frequent ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
(Date:9/1/2015)... ... September 01, 2015 , ... Virginia entrepreneur ... is still strongly maintaining her firm’s success in the hair care and distribution ... upcoming city-to-city tour, Ellis will be providing “Look and learn” live demonstrations, as ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... ranked a top-five hospital by U.S. News & World Report, to provide breaking ... , Editorial and marketing groups within OncLive, which provides oncologists resources and ...
(Date:9/1/2015)... ... 01, 2015 , ... The Jerry Segal Classic to benefit the patients of ... Country Club in Lafayette Hill, PA. Over the past 26 years, the Classic, organized ... and services designed to support patients and their families during their time at Magee ...
(Date:9/1/2015)... , ... September 01, 2015 , ... With former IBMers ... and Math) disciplines since its inception more than 35 years ago. A pilot program ... and their teachers - and, not just those intent on pursuing careers in these ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... announced the release of version 5.2 of the FirstSpirit Content Management System with ... initiative. With the new version of FirstSpirit, companies will be well on their ...
Breaking Medicine News(10 mins):Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3
... By Amanda Gardner HealthDay Reporter , TUESDAY, Jan. ... moved to rescind approval of the drug Avastin to treat ... anti-cancer medication ups the odds of congestive heart failure in ... the Journal of Clinical Oncology , included almost 4,000 ...
... Researchers have produced a lasting anti-cocaine immunity in mice by ... cold virus with a particle that mimics cocaine. , ... the online edition of Molecular Therapy and funded by ... strategy might be the first to offer cocaine addicts a fairly ...
... -- Elderly people who lose their teeth may be at ... study included more than 4,000 Japanese participants, 65 and older, ... with participants who still had many of their natural teeth, ... to have experienced some memory loss or have early-stage Alzheimer,s ...
... cortical nerve cells or neurons reside in the brain,s gray ... matter, but some people with schizophrenia have a higher number ... arise in schizophrenia as a consequence of both genetic and ... has now been studied in detail in a paper by ...
... , New Rochelle, NY, January 4, 2011Lowering the body ... severe brain injury may reduce neurologic complications and improve ... injury (TBI) has been demonstrated in national studies. According ... field, when and how it is administered should depend ...
... TUCSON, Ariz. (January 4, 2011) -- Cumbersome glaucoma tests ... history thanks to a home test developed by an ... hand-held instrument involving a system of micro-force sensors, specially ... by researchers at the UA College of Engineering. The ...
Cached Medicine News:Health News:More Evidence Links Avastin to Heart Failure in Breast Cancer Patients 2Health News:More Evidence Links Avastin to Heart Failure in Breast Cancer Patients 3Health News:Vaccine blocks cocaine high in mice 2Health News:Vaccine blocks cocaine high in mice 3Health News:Neuronal migration errors: Right cells, wrong place 2Health News:Optimizing patient outcomes after therapeutic hypothermia for traumatic brain injury 2Health News:New glaucoma test allows earlier, more accurate detection 2
... the newest and most advanced automated immunoassay ... AIA-1800 launches with a full menu of ... reproductive, cardiac, and anemia assays. ,The AIA-1800 ... primary tube sampling, auto dilution, auto pretreatment, ...
EZ-PSA is a one-step immunoassay for the rapid, qualitative determination of human Prostate Specific Antigen (PSA) in whole blood. The test is intended for professional use as an aid in the diagnosis...
... name from its first known site of ... of PSA circulates bound to anti-chymotrypsin (PSA-ACT) ... PSA are elevated in patients with prostate ... [1-3]. In addition, PSA serum levels appear ...
... Functional Vision, Quality of Vision and ... both target illumination and glare luminance ... results. Day/Night testing with/without glare and ... and all ANSI standards. All Light ...
Medicine Products: